Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 565

1.

Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.

Straus DJ, Długosz-Danecka M, Alekseev S, Illes A, Picardi M, Lech-Maranda E, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Ramchandren R, Zinzani PL, Hutchings M, Connors JM, Radford J, Munoz J, Kim WS, Advani R, Ansell SM, Younes A, Miao H, Liu R, Fenton K, Forero A, Gallamini A.

Blood. 2020 Jan 16. pii: blood.2019003127. doi: 10.1182/blood.2019003127. [Epub ahead of print]

PMID:
31945149
2.

Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma.

Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Gerecitano JF, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Luminari S, Marcheselli L, Federico M, Younes A.

Eur J Cancer. 2020 Jan 8;126:78-90. doi: 10.1016/j.ejca.2019.12.006. [Epub ahead of print]

PMID:
31927165
3.

Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma.

Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR.

Cancer Discov. 2020 Jan 8. pii: CD-19-0116. doi: 10.1158/2159-8290.CD-19-0116. [Epub ahead of print]

4.

Follicular lymphoma.

Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J.

Nat Rev Dis Primers. 2019 Dec 12;5(1):83. doi: 10.1038/s41572-019-0132-x. Review.

PMID:
31831752
5.

Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution.

Joffe E, Kumar A, Zheng S, Uppal M, Bantilan KS, Atteberry P, Straus DJ, Palomba ML, Noy A, Horwitz SM, Moskowitz AJ, Hamlin PA, Matasar MJ, Batlevi CL, von Keudell GR, Dogan A, Younes A, Zelenetz AD.

Blood. 2019 Nov 13;134(Supplement_1):22. doi: 10.1182/blood-2019-129563.

PMID:
31724028
6.

Paradigms for Precision Medicine in Epichaperome Cancer Therapy.

Pillarsetty N, Jhaveri K, Taldone T, Caldas-Lopes E, Punzalan B, Joshi S, Bolaender A, Uddin MM, Rodina A, Yan P, Ku A, Ku T, Shah SK, Lyashchenko S, Burnazi E, Wang T, Lecomte N, Janjigian Y, Younes A, Batlevi CW, Guzman ML, Roboz GJ, Koziorowski J, Zanzonico P, Alpaugh ML, Corben A, Modi S, Norton L, Larson SM, Lewis JS, Chiosis G, Gerecitano JF, Dunphy MPS.

Cancer Cell. 2019 Nov 11;36(5):559-573.e7. doi: 10.1016/j.ccell.2019.09.007. Epub 2019 Oct 24.

PMID:
31668946
7.

Thymic Mucoepidermoid Carcinoma: A Systematic Review and Meta-analysis.

Hamza A, Younes AI, Kalhor N.

Adv Anat Pathol. 2019 Nov;26(6):341-345. doi: 10.1097/PAP.0000000000000250.

PMID:
31593977
8.

Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.

Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW.

Clin Cancer Res. 2019 Dec 15;25(24):7576-7584. doi: 10.1158/1078-0432.CCR-19-0795. Epub 2019 Sep 20.

PMID:
31540976
9.

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.

Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW.

JAMA Oncol. 2019 Sep 17. doi: 10.1001/jamaoncol.2019.2809. [Epub ahead of print]

PMID:
31529018
10.

Clinical features and outcome of hepatosplenic fungal infections in children with haematological malignancies.

Madney Y, Shalaby L, Elanany M, Adel N, Nasr E, Alsheshtawi K, Younes A, Hafez H.

Mycoses. 2020 Jan;63(1):30-37. doi: 10.1111/myc.13002. Epub 2019 Nov 13.

PMID:
31514231
11.

Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy.

Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI, Cortez MA, Erasmus JJ, de Groot P, Carter BW, Hong DS, Glitza IC, Ferrarotto R, Altan M, Diab A, Chun SG, Heymach JV, Tang C, Nguyen QN, Welsh JW.

J Immunother Cancer. 2019 Sep 4;7(1):237. doi: 10.1186/s40425-019-0718-6.

12.

The application of poorly crystalline silicotitanate in production of 225Ac.

Fitzsimmons J, Abraham A, Catalano D, Younes A, Cutler CS, Medvedev D.

Sci Rep. 2019 Aug 14;9(1):11808. doi: 10.1038/s41598-019-48021-7.

13.

Reply to M. Skelin et al.

Wilson WH, Staudt L, Younes A.

J Clin Oncol. 2019 Oct 1;37(28):2584-2585. doi: 10.1200/JCO.19.01603. Epub 2019 Aug 7. No abstract available.

PMID:
31390273
14.

Efficacy of platelet-rich plasma plus fractional carbon dioxide laser in treating posttraumatic scars.

Makki M, Younes AEKH, Fathy A, Abd ElDayem OY, Morsy H.

Dermatol Ther. 2019 Sep;32(5):e13031. doi: 10.1111/dth.13031. Epub 2019 Aug 5.

PMID:
31344305
15.

Will GALEN become more RELEVANT?

von Keudell G, Younes A.

Lancet Haematol. 2019 Aug;6(8):e391-e392. doi: 10.1016/S2352-3026(19)30136-X. Epub 2019 Jul 8. No abstract available.

PMID:
31296424
16.

Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

Bhupathiraju NVSDK, Younes A, Cao M, Ali J, Cicek HT, Tully KM, Ponnala S, Babich JW, Deri MA, Lewis JS, Francesconi LC, Drain CM.

Org Biomol Chem. 2019 Jul 17;17(28):6866-6871. doi: 10.1039/c9ob01068h.

PMID:
31268109
17.

Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.

Wang S, Mondal S, Zhao C, Berishaj M, Ghanakota P, Batlevi CL, Dogan A, Seshan VE, Abel R, Green MR, Younes A, Wendel HG.

JCI Insight. 2019 Jun 20;4(12). pii: 127566. doi: 10.1172/jci.insight.127566. eCollection 2019 Jun 20.

18.

Magnetically modified hydroxyapatite nanoparticles for the removal of uranium (VI): Preparation, characterization and adsorption optimization.

El-Maghrabi HH, Younes AA, Salem AR, Rabie K, El-Shereafy ES.

J Hazard Mater. 2019 Oct 15;378:120703. doi: 10.1016/j.jhazmat.2019.05.096. Epub 2019 May 30.

PMID:
31203125
19.

New drugs for new targets in lymphoma.

Younes A.

Hematol Oncol. 2019 Jun;37 Suppl 1:105-109. doi: 10.1002/hon.2592. Review. No abstract available.

PMID:
31187529
20.

Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma.

El-Kholy E, El Nadi E, Hafez H, Ahmed S, Younes A, El-Kenanii N, Khalid E.

Nucl Med Commun. 2019 Sep;40(9):898-904. doi: 10.1097/MNM.0000000000001040.

PMID:
31145205
21.

Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse.

Kumar A, Sha F, Toure A, Dogan A, Ni A, Batlevi CL, Palomba MLM, Portlock C, Straus DJ, Noy A, Horwitz SM, Moskowitz A, Hamlin P, Moskowitz CH, Matasar MJ, Zelenetz AD, Younes A.

Blood Cancer J. 2019 May 20;9(6):50. doi: 10.1038/s41408-019-0209-5.

22.

Stability After Initial Decline in Coronary Revascularization Rates in the United States.

Raza S, Deo SV, Kalra A, Zia A, Altarabsheh SE, Deo VS, Mustafa RR, Younes A, Rao SV, Markowitz AH, Park SJ, Costa MA, Simon DI, Bhatt DL, Sabik JF 3rd.

Ann Thorac Surg. 2019 Nov;108(5):1404-1408. doi: 10.1016/j.athoracsur.2019.03.080. Epub 2019 Apr 27.

PMID:
31039350
23.

Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.

Kumar A, Ying Z, Alperovich A, Dogan A, Hamlin P, Moskowitz C, Pichardo J, Portlock C, Sha F, Zelenetz AD, Zhang Z, Drill E, Woo K, Younes A.

Haematologica. 2019 Apr;104(4):e163-e166. doi: 10.3324/haematol.2018.201350. No abstract available.

24.

IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Li A, Barsoumian HB, Schoenhals JE, Caetano MS, Wang X, Menon H, Valdecanas DR, Niknam S, Younes AI, Cortez MA, Welsh JW.

Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):903-912. doi: 10.1016/j.ijrobp.2019.03.022. Epub 2019 Mar 21.

PMID:
30905636
25.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators.

J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.

26.

Corrigendum to 'Surgery in perforated pediatric intestinal lymphoma' [European Journal of Surgical Oncology 45 (2019) 279-283].

Ahmed G, ElShafiey M, Abdelrahman H, Semary S, Elkinaai N, Romeih M, Mohy R, Younes A.

Eur J Surg Oncol. 2019 May;45(5):928. doi: 10.1016/j.ejso.2019.02.024. Epub 2019 Mar 7. No abstract available.

PMID:
30853169
27.

Emerging epigenetic-modulating therapies in lymphoma.

Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A.

Nat Rev Clin Oncol. 2019 Aug;16(8):494-507. doi: 10.1038/s41571-019-0190-8. Review.

28.

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.

Khashab T, Hagemeister F, Romaguera JE, Fanale MA, Pro B, McLaughlin P, Rodriguez MA, Neelapu SS, Fayad L, Younes A, Feng L, Vega F, Kwak LW, Samaniego F.

Br J Haematol. 2019 May;185(4):670-678. doi: 10.1111/bjh.15814. Epub 2019 Feb 28.

PMID:
30820940
29.

Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.

Borchmann S, Joffe E, Moskowitz CH, Zelenetz AD, Noy A, Portlock CS, Gerecitano JF, Batlevi CL, Caron PC, Drullinsky P, Hamilton A, Hamlin PA Jr, Horwitz SM, Kumar A, Matasar MJ, Moskowitz AJ, Owens CN, Palomba ML, Younes A, Straus DJ.

Blood. 2019 May 16;133(20):2121-2129. doi: 10.1182/blood-2018-10-877761. Epub 2019 Feb 15.

PMID:
30770396
30.

Structured crowdsourcing enables convolutional segmentation of histology images.

Amgad M, Elfandy H, Hussein H, Atteya LA, Elsebaie MAT, Abo Elnasr LS, Sakr RA, Salem HSE, Ismail AF, Saad AM, Ahmed J, Elsebaie MAT, Rahman M, Ruhban IA, Elgazar NM, Alagha Y, Osman MH, Alhusseiny AM, Khalaf MM, Younes AF, Abdulkarim A, Younes DM, Gadallah AM, Elkashash AM, Fala SY, Zaki BM, Beezley J, Chittajallu DR, Manthey D, Gutman DA, Cooper LAD.

Bioinformatics. 2019 Sep 15;35(18):3461-3467. doi: 10.1093/bioinformatics/btz083.

31.

Is hydroxypyridonate 3,4,3-LI(1,2-HOPO) a good competitor of fetuin for uranyl metabolism?

Younes A, Creff G, Beccia MR, Moisy P, Roques J, Aupiais J, Hennig C, Solari PL, Den Auwer C, Vidaud C.

Metallomics. 2019 Feb 20;11(2):496-507. doi: 10.1039/c8mt00272j.

PMID:
30644488
32.

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

Younes A, Brody J, Carpio C, Lopez-Guillermo A, Ben-Yehuda D, Ferhanoglu B, Nagler A, Ozcan M, Avivi I, Bosch F, Caballero Barrigón MD, Hellmann A, Kuss B, Ma DDF, Demirkan F, Yağci M, Horowitz NA, Marlton P, Cordoba R, Wrobel T, Buglio D, Streit M, Hodkinson BP, Schaffer M, Alvarez J, Ceulemans R, Balasubramanian S, de Jong J, Wang SS, Fourneau N, Jurczak W.

Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.

PMID:
30642819
33.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
34.

Appropriate use criteria adoption for PCI at an academic medical center.

Younes A, Hoff JS, Bojansky AM, Kalra A.

Eur Heart J. 2018 Dec 14;39(47):4136-4138. doi: 10.1093/eurheartj/ehy756. Review. No abstract available.

PMID:
30551141
35.

Seroprevalence, isolation, molecular detection and genetic diversity of Toxoplasma gondii from small ruminants in Egypt.

Abd El-Razik KA, Barakat AMA, Hussein HA, Younes AM, Elfadaly HA, Eldebaky HA, Soliman YA.

J Parasit Dis. 2018 Dec;42(4):527-536. doi: 10.1007/s12639-018-1029-4. Epub 2018 Oct 15.

36.

Novel therapeutic agents for relapsed classical Hodgkin lymphoma.

von Keudell G, Younes A.

Br J Haematol. 2019 Jan;184(1):105-112. doi: 10.1111/bjh.15695. Epub 2018 Dec 11. Review.

PMID:
30536386
37.

Phase I/II study of dasatinib and exploratory genomic analysis in relapsed or refractory non-Hodgkin lymphoma.

Umakanthan JM, Iqbal J, Batlevi CL, Bouska A, Smith LM, Shostrom V, Nutsch H, William BM, Gregory Bociek R, Lunning M, Bierman P, Younes A, Armitage JO, Vose JM.

Br J Haematol. 2019 Mar;184(5):744-752. doi: 10.1111/bjh.15702. Epub 2018 Dec 5.

PMID:
30520026
38.

Endovascular Embolization of Post-tonsillectomy Pseudoaneurysm: A Single-Center Case Series.

Hassan F, Younes A, Rifai M.

Cardiovasc Intervent Radiol. 2019 Apr;42(4):528-533. doi: 10.1007/s00270-018-2131-9. Epub 2018 Dec 5.

PMID:
30519726
39.

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.

Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J, Fowler N, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG, Fayad L, Piha-Paul S, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR, Hong DS.

J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.

40.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2018 Nov 15;3(22). pii: 125568. doi: 10.1172/jci.insight.125568. No abstract available.

41.

Excitation-Dependent Multiple Fluorescence of a Substituted 2-(2'-Hydroxyphenyl)benzoxazole.

Meisner QJ, Younes AH, Yuan Z, Sreenath K, Hurley JJM, Zhu L.

J Phys Chem A. 2018 Nov 29;122(47):9209-9223. doi: 10.1021/acs.jpca.8b07988. Epub 2018 Nov 15.

PMID:
30411891
42.

NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death.

Liu Y, Mondello P, Erazo T, Tannan NB, Asgari Z, de Stanchina E, Nanjangud G, Seshan VE, Wang S, Wendel HG, Younes A.

Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):12034-12039. doi: 10.1073/pnas.1806928115. Epub 2018 Nov 7.

43.

Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism.

Nafee T, Gibson CM, Yee MK, Alkhalfan F, Chi G, Travis R, Mir M, Kalayci A, Jafarizade M, Ganti A, Kazmi SH, Ghaffarpasand E, Pitliya A, Datta S, Sharfaei S, Alihashemi M, Elsaiey A, Qamar I, Jahansouz M, Talib U, Kahe F, Habibi S, Abdelwahed M, Tariq F, Kaur M, Younes A, Walia SS, Singh A, Dildar SM, Afzal MK, Kerneis M.

Expert Rev Cardiovasc Ther. 2018 Nov;16(11):845-855. doi: 10.1080/14779072.2018.1534068. Epub 2018 Oct 15. Review.

PMID:
30296387
44.

Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.

Schoenhals JE, Cushman TR, Barsoumian HB, Li A, Cadena AP, Niknam S, Younes AI, Caetano MDS, Cortez MA, Welsh JW.

Front Immunol. 2018 Sep 20;9:2170. doi: 10.3389/fimmu.2018.02170. eCollection 2018.

45.

Surgery in perforated pediatric intestinal lymphoma.

Ahmed G, ElShafiey M, Abdelrahman H, Semary S, Elkinaai N, Romeih M, Mohy R, Younes A.

Eur J Surg Oncol. 2019 Feb;45(2):279-283. doi: 10.1016/j.ejso.2018.08.022. Epub 2018 Sep 6. Erratum in: Eur J Surg Oncol. 2019 May;45(5):928.

PMID:
30224248
46.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

47.

BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors.

Derenzini E, Mondello P, Erazo T, Portelinha A, Liu Y, Scallion M, Asgari Z, Philip J, Hilden P, Valli D, Rossi A, Djaballah H, Ouerfelli O, de Stanchina E, Seshan VE, Hendrickson RC, Younes A.

Cell Rep. 2018 Aug 21;24(8):2155-2166. doi: 10.1016/j.celrep.2018.07.055.

48.

Lymphocyte-to-Monocyte Ratio May Serve as a Better Prognostic Indicator Than Tumor-associated Macrophages in DLBCL Treated With Rituximab.

Matsuki E, Bohn OL, El Jamal S, Pichardo JD, Zelenetz AD, Younes A, Teruya-Feldstein J.

Appl Immunohistochem Mol Morphol. 2019 Sep;27(8):572-580. doi: 10.1097/PAI.0000000000000645.

PMID:
30106758
49.

Is Polonium-210 a Good Indicator for Anthropogenic Radioactivity?

Younes A, Alliot C, Mokili M, Montavon G.

Cancer Biother Radiopharm. 2018 Oct;33(8):356-360. doi: 10.1089/cbr.2018.2496. Epub 2018 Aug 8.

PMID:
30088970
50.

Phytochemical Screening and Antidiabetic, Antihyperlipidemic, and Antioxidant Properties of Anthyllis henoniana (Coss.) Flowers Extracts in an Alloxan-Induced Rats Model of Diabetes.

Ben Younes A, Ben Salem M, El Abed H, Jarraya R.

Evid Based Complement Alternat Med. 2018 Jun 24;2018:8516302. doi: 10.1155/2018/8516302. eCollection 2018.

Supplemental Content

Loading ...
Support Center